THE INVESTOR

메뉴열기
August 05, 2020

Vaccine developer SK Bioscience plans 2021 IPO

PUBLISHED : July 27, 2020 - 09:55

UPDATED : July 27, 2020 - 09:55

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

SK Group is pushing for another initial public offering of its health care affiliate SK Bioscience, just a month after SK Biopharmaceuticals’ record-breaking stock market entry last month.

SK Bioscience, a vaccine developer that was spun-off from SK Chemical in July 2018, will reportedly file for listing next year. 

SK Bioscience



Both NHIS and KIS were underwriters responsible for the blockbuster IPO of SK Biopharmaceuticals, a drug company that specializes in research and development of treatments for central nervous system disorders.

SK Biopharmaceuticals shares were 323 times oversubscribed, buoyed by the fact that it already has approval from the US Food and Drug Administration for solriamfetol and cenobamate.

SK Bioscience is a vaccines research and manufacturing business that is pursuing COVID-19 vaccines research under a state-run project.

The Bill & Melinda Gates Foundation funded $3.6 million for SK Bioscience’s efforts to peg an optimal antigen for COVID-19.

On top of its own research, SK Bioscience recently signed contract with AstraZeneca to contract manufacture the latter’s COVID-19 vaccines in Korea upon successful completion of development.

SK Bioscience has experience in successful development of cell-cultured flu vaccine, cervical cancer vaccine and pediatric enteritis vaccine. It also has its own good manufacturing practice-abiding facility.

A company official said that SK Bioscience’s IPO will be carried out if it receives a “fair evaluation of its corporate value.”

SK Bioscience is 98.04 percent owned by SK Chemical, which is 33.47 percent owned by SK Discovery, which is 40.18 percent owned by SK Group Vice Chairman Chey Chang-won.

Chey Chang-won is a cousin of SK Group Chairman Chey Tae-won, who has 18.44 percent stake in SK Holdings.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.